Leadership & Pay ·
Arcutis Biotherapeutics, Inc. increased its Board of Directors from nine to ten members and appointed Christopher…
ARQTArcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. increased its Board of Directors from nine to ten members and appointed Christopher Peetz as a new Class III director, effective July 15, 2026. Mr. Peetz, a biopharmaceutical executive with experience at Mirum Pharmaceuticals and Tobira Therapeutics, will receive an initial stock option award for 21,486 shares and is eligible for a prorated annual equity award valued at approximately $350,000 and a $50,000 cash retainer. Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing therapies for chronic inflammatory skin diseases.